MedPath

Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold. - Peri-operative effects of dopexamine in patients with low AT

Phase 1
Conditions
Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).
Registration Number
EUCTR2006-002913-11-GB
Lead Sponsor
York Hospitals NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
124
Inclusion Criteria

Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients less than 60 years of age unless they have significant co morbidities (ASA 3 or greater), patients having emergency or vascular procedures, those who are ASA grade 5, and patients who refuse or are unable to give informed consent

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath